HERON THERAPEUTICS, INC. /DE/
No enriched coverage for $HRTX in the last 7 days.
No SEC Form 4 filings for $HRTX in the last 30 days.
See all $HRTX insider activity →Fulcrum Therapeutics (FULC) fell 51% to a 52-week low of $2.9 after halting development of its lead sickle cell disease treatment due to FDA cancer risk concerns. Heron Therapeutics (HRTX) dropped 45% to $0.44 following a court ruling invalidating key patents for CINVANTI. MicroVision (MVIS) declined 32% to $0.4 after proposing a reverse stock split to meet Nasdaq requirements.
Heron Therapeutics (HRTX) reported Q2 2026 net revenue of $37.7M, up from $34.7M in Q1 but below expectations. CINVANTI was $21.8M, ZYNRELEF $11.1M (+35% YoY), and APONVIE $4.2M (+74% YoY). After a June patent ruling, the company amended its Hercules credit facility, resetting covenants through 2027 and reducing principal. It withdrew full-year 2026 guidance.
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 13, 2026, Heron Therapeutics, Inc. (the “Company”) entered into Amendment No. 1 to Tax Benefit Preservation Plan (the “Amendment”), which amends the Tax Benefit Preservation Plan, dated as of August 14, 2025 (the “Pl
Recent HRTX coverage spans financial news, earnings and corporate actions.
Patent invalidation could allow generics, hurting sales outlook.
Balance-sheet reset and covenant relief reduce near-term financial risk, while product demand trends and guidance withdrawal shape the risk/reward for the stock.
The plan extension is a capital-structure and ownership-dilution risk-management move, likely limiting certain transactions that could trigger tax-asset impairment.
Guidance withdrawal and covenant-linked debt amendment increase near-term risk around cash runway and competitive overhang from a potential CINVANTI generic.
Guidance withdrawal and forecast uncertainty around CINVANTI generic-entry timing are likely to pressure near-term expectations while ZYNRELEF and APONVIE growth partially offsets.
alphai scores every news story that mentions HRTX with an AI model for sentiment and relevance, and aggregates insider trades from HERON THERAPEUTICS, INC. /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Fulcrum Therapeutics (FULC) fell 51% to a 52-week low of $2.9 after halting development of its lead sickle cell disease treatment due to FDA cancer risk concerns. Heron Therapeutics (HRTX) dropped 45% to $0.44 following a court ruling invalidating key patents for CINVANTI. MicroVision (MVIS) declined 32% to $0.4 after proposing a reverse stock split to meet Nasdaq requirements.
2 min readHeron Therapeutics (HRTX) reported Q2 2026 net revenue of $37.7M, up from $34.7M in Q1 but below expectations. CINVANTI was $21.8M, ZYNRELEF $11.1M (+35% YoY), and APONVIE $4.2M (+74% YoY). After a June patent ruling, the company amended its Hercules credit facility, resetting covenants through 2027 and reducing principal. It withdrew full-year 2026 guidance.
7 min readHERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 13, 2026, Heron Therapeutics, Inc. (the “Company”) entered into Amendment No. 1 to Tax Benefit Preservation Plan (the “Amendment”), which amends the Tax Benefit Preservation Plan, dated as of August 14, 2025 (the “Pl
2 min readHeron Therapeutics (NASDAQ:HRTX) reported Q2 sales of about $4.2M for APONVIE, up 26% QoQ and 74% YoY, and $21.8M for CINVANTI, down about 10% YoY. SUSTOL contributed $0.5M as wind-down continued. Heron posted a Q2 net loss of $5.5M, gross margin 69.3%, and ended with $42.7M cash equivalents. It amended its Hercules credit facility with a $13.5M principal reduction and potential $4M more, and withdrew 2026 guidance.
6 min readHERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-year - Amended credit facility with Hercules
6 min readHERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0000818033 false 0000818033 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,
2 min readHeron Therapeutics (Nasdaq: HRTX) announced it will report its first-quarter 2026 financial results and discuss business highlights on Monday, May 11, 2026, at 8:30 a.m. ET. The event will include a conference call and live webcast accessible through registration on the company's investor relations website, where an archive will also be available for 60 days. Investors are advised to register and dial in 15 minutes early to avoid delays.
2 min readHeron Therapeutics announced it will report its first quarter 2026 financial results on Monday, May 11, 2026, through a conference call and live webcast. The event, scheduled for 8:30 a.m. ET, will also cover recent business highlights. Interested parties can access dial-in details via a registration link or the Investor Relations section of the company's website.
2 min readAlthough the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2 min readHeron Therapeutics (HRTX) delivered earnings and revenue surprises of -150.00% and -0.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
